TY - JOUR
T1 - Does it matter whether a T1 high-grade tumor is molecularly classified?
AU - Stenzl, Arnulf
AU - McConkey, David
AU - Bellmunt, Joaquim
N1 - Funding Information:
Financial disclosures : Arnulf Stenzl certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Arnulf Stenzl acknowledges the following support: grants or funding: Amgen Inc., Bayer AG, Cepheid, CureVac, GemDx Biosciences, Immatics Biotechnology, Johnson&Johnson, Karl Storz AG, Novartis AG, and Roche; honoraria: Alere, Astellas, Bristol-Myers-Squibb, CureVac, Ferring, Ipsen Pharma, Janssen, Roche, Sanofi Aventis, Stebabiotech, and Synergo. David McConkey acknowledges the following support: grants or funding: Astra-Zeneca; honoraria: Janssen and Bioclin. Joaquim Bellmunt acknowledges the following support: grants or funding: Pfizer/MSD and Takeda; consultancies: Astra Zeneca and Roche; honoraria: Roche and Merck; royalties or patents: UpToDate.
Publisher Copyright:
© 2021 European Association of Urology
PY - 2021/10
Y1 - 2021/10
N2 - A 58-yr-old male, 20 pack-year smoker, with hypertension was diagnosed with a single left-side high-grade papillary tumor with peritumoral carcinoma in situ, but no tumor was visible outside the bladder. En bloc resection was performed, and repeat transurethral resection of the bladder at 4 wk found no residual tumor. He was prescribed bacillus Calmette-Guérin (BCG) plus maintenance therapy, and cystoscopy at 9 mo found a T1b high-grade tumor, this time right sided. Is it important that the tumor should be molecularly characterized before a treatment decision is made, or is clinicopathologic characterization still the only viable option at this time? Patient summary: We discussed how new methods in pathology may help us find molecular structures that would help clinicians decide safely between cystectomy and conservative bladder-sparing strategies. The primary superficially infiltrative tumor and its similar recurrence 9 mo later were categorized based on standard clinical criteria, but here we discuss whether recently discovered methods for defining the molecular structure of tumors could mean that more bladder-preserving treatments might be an option.
AB - A 58-yr-old male, 20 pack-year smoker, with hypertension was diagnosed with a single left-side high-grade papillary tumor with peritumoral carcinoma in situ, but no tumor was visible outside the bladder. En bloc resection was performed, and repeat transurethral resection of the bladder at 4 wk found no residual tumor. He was prescribed bacillus Calmette-Guérin (BCG) plus maintenance therapy, and cystoscopy at 9 mo found a T1b high-grade tumor, this time right sided. Is it important that the tumor should be molecularly characterized before a treatment decision is made, or is clinicopathologic characterization still the only viable option at this time? Patient summary: We discussed how new methods in pathology may help us find molecular structures that would help clinicians decide safely between cystectomy and conservative bladder-sparing strategies. The primary superficially infiltrative tumor and its similar recurrence 9 mo later were categorized based on standard clinical criteria, but here we discuss whether recently discovered methods for defining the molecular structure of tumors could mean that more bladder-preserving treatments might be an option.
KW - DNA damage and repair mutations
KW - Genomic profiling
KW - Muscle-invasive bladder cancer
KW - Muscle-invasive, Non–muscle-invasive bladder cancer
KW - The Cancer Genomic Atlas
KW - UROMOL
UR - http://www.scopus.com/inward/record.url?scp=85070021931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070021931&partnerID=8YFLogxK
U2 - 10.1016/j.euo.2019.07.009
DO - 10.1016/j.euo.2019.07.009
M3 - Article
C2 - 31383572
AN - SCOPUS:85070021931
SN - 2588-9311
VL - 4
SP - 837
EP - 842
JO - European Urology Oncology
JF - European Urology Oncology
IS - 5
ER -